Press Releases

Johnson & Johnson announced it has initiated the submission of an original New Drug Application with the U.S. Food and Drug Administration (FDA) for TAR-200 for the treatment of patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS), with or without papillary tumors. This submission is being reviewed by the FDA through the Real-Time Oncology Review (RTOR) program, which allows the FDA to re

Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector (SC-AI) for weekly maintenance dosing. LEQEMBI is indicated for the treatment of Alzheimer’s disease (AD) in patients with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). A Prescription Drug User

International Isotopes, Inc. is excited to announce a strategic expansion of its company footprint with the recent purchase of vacant land adjacent to its current Idaho Falls facility ("Building A"). The Company has also entered a lease agreement, with the right to purchase the property, for a second building, which is located directly across the street from their Idaho Falls facility ("Building B"). These two forward-looking additions address both immediate needs for curr

Sen-Jam Pharmaceutical, a leader in innovative anti-inflammatory care, today announced the submission of a new patent application that introduces a novel composition and method to target obesity and metabolic disorders. The patent focuses on leveraging a synergistic combination of a mast cell stabilizer, H1-antihistamine, and non-steroidal anti-inflammatory drugs (NSAIDs) to address chronic low-grade inflammation—the root cause of many metabolic dysfunctions. Chronic inflammat

Veralox Therapeutics, a clinical-stage biotechnology company developing a new class of therapies targeting the 12-lipoxygenase (12-LOX) pathway, announced today that it has entered into an exclusive agreement with Nudge Therapeutics to acquire the company and their preclinical cyclic AMP-GMP (cGAS) inhibitor compounds.  The agreement allows Veralox to continue development of Nudge's compounds and trigger acquisition of the company upon achievement of downstream milestones. Financial

Vividion Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing novel discovery technologies to unlock high-value, traditionally undruggable targets and develop small molecule precision therapeutics for devastating cancers and immune disorders, today announced the acquisition of Tavros Therapeutics, Inc., a precision oncology platform company. Vividion is a wholly owned and independently operating subsidiary of Bayer AG. The addition of Tavros greatly expands Vivid

COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, has secured Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for CNP-104 for the treatment of primary biliary cholangitis (PBC). “Receiving Orphan Drug Designation for CNP-104 underscores its potential to become the first disease-modifying treatment for ind

QUANTRO Therapeutics, a pioneer in the discovery of first-in-class transcription factor targeting cancer treatments, announced today that the company has successfully completed its first ten-target multiplex-screening campaign, which yielded validated hits and functional proof of on-target activity for multiple molecular targets. This milestone further expands the capability to establish QUANTRO’s innovative QUANTROseq® platform as a pioneering technology in the fight against diseas

GenScript Biotech Corporation, a global leader in life sciences research and manufacturing services, has officially joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner. This milestone marks significant progress in GenScript's journey of fulfilling its social responsibility and advancing sustainable development, while underscoring the company's commitment to building a healthier, greener, and more ethical industry ecosystem. PSCI is a leading global

Merck, a leading science and technology company, announced the closing of the transaction to acquire HUB Organoids Holding B.V. (HUB) following regulatory clearances and the fulfilment of other customary closing conditions. The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for more f